XyloCor Therapeutics, a King of Prussia, PA-based clinical stage biopharmaceutical company developing novel gene therapies for cardiovascular disease, raised $67.5M in Series B financing.
The round was led by Jeito Capital with participation from existing investors EQT, Fountain Healthcare Partners, and Lumira Ventures. Rachel Mears, Partner at Jeito Capital, will join the XyloCor Board of Directors.
The company intends to use the funds to support two double-blind Phase 2 clinical trials of lead candidate, XC001, which has demonstrated transformative potential for treatment of refractory angina
Led by CEO Al Gianchetti, president and chief executive officer, XyloCor Therapeutics is a clinical‑stage biopharmaceutical company developing XC001 to investigate use for patients with ischemic heart disease for whom there are no treatment options. XyloCor has a second preclinical investigational product, XC002, in discovery stage, being developed for the treatment of patients with cardiac tissue damage from heart attacks.
The company, which was co‑founded by Ronald Crystal, M.D., and Todd Rosengart, M.D., has an exclusive license from Cornell University.
FinSMEs
08/01/2024